Status:
NOT_YET_RECRUITING
Cladribine Tablets as an Exit Therapy Strategy
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis
Eligibility:
All Genders
45+ years
Brief Summary
The objective of the study is to evaluate the effectiveness of CladT, in terms of disease stability and safety, as the last treatment option in ageing MS patients vs treatment continuation and discont...
Eligibility Criteria
Inclusion
- Patient ≥45-year-old with RRMS
- Disease duration ≥10 years
- No evidence of disease activity ≥5 years under DMT
- EDSS score between 0 and 6.0 included
Exclusion
- Progressive form of MS
- Patients without DMT
- EDSS score ≥6.5
Key Trial Info
Start Date :
June 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT06887426
Start Date
June 1 2025
End Date
December 1 2025
Last Update
June 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de neurologie - Hôpitaux Universitaires de Strasbourg
Strasbourg, France, 67000